CRISPR-Clear Imaging of Melanin-Rich B16-Derived Solid Tumors

Researchers developed a CRISPR-based gene editing approach, which they termed CRISPR-Clear, that was easily incorporated into existing tissue-clearing workflows, and they demonstrated its applicability to highly melanin-rich B16-derived solid tumors.